ATE335504T1 - Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben - Google Patents

Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben

Info

Publication number
ATE335504T1
ATE335504T1 AT99924395T AT99924395T ATE335504T1 AT E335504 T1 ATE335504 T1 AT E335504T1 AT 99924395 T AT99924395 T AT 99924395T AT 99924395 T AT99924395 T AT 99924395T AT E335504 T1 ATE335504 T1 AT E335504T1
Authority
AT
Austria
Prior art keywords
humanized antibodies
producing
same
cell line
verotoxin
Prior art date
Application number
AT99924395T
Other languages
English (en)
Inventor
Yoh-Ichi Matsumoto
Atsuchi Imaizumi
Tsuyoshi Kimura
Tae Takedo
Man Sung Co
Maximiliano Vasques
Original Assignee
Teijin Ltd
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Protein Design Labs Inc filed Critical Teijin Ltd
Application granted granted Critical
Publication of ATE335504T1 publication Critical patent/ATE335504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99924395T 1998-05-20 1999-05-19 Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben ATE335504T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8657098P 1998-05-20 1998-05-20

Publications (1)

Publication Number Publication Date
ATE335504T1 true ATE335504T1 (de) 2006-09-15

Family

ID=22199443

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99924395T ATE335504T1 (de) 1998-05-20 1999-05-19 Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben

Country Status (19)

Country Link
US (1) US7846435B1 (de)
EP (1) EP1079856B1 (de)
JP (1) JP4044733B2 (de)
KR (1) KR100548167B1 (de)
CN (1) CN1330375C (de)
AT (1) ATE335504T1 (de)
AU (1) AU748852B2 (de)
BR (1) BR9910589A (de)
CA (1) CA2328485C (de)
DE (1) DE69932719T2 (de)
DK (1) DK1079856T3 (de)
ES (1) ES2270598T3 (de)
IL (2) IL139571A0 (de)
NO (1) NO326197B1 (de)
NZ (1) NZ508119A (de)
PT (1) PT1079856E (de)
RU (1) RU2217166C2 (de)
WO (1) WO1999059629A1 (de)
ZA (1) ZA200006370B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
AU2007240614B2 (en) 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein
US8969529B2 (en) 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
CN105555293B (zh) * 2013-05-27 2021-08-03 英母拓公司 布鲁氏菌属2,4-二氧四氢蝶啶合酶和AB5毒素β亚基的嵌合体
SG10201806025TA (en) * 2014-01-16 2018-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3236667B2 (ja) 1991-06-28 2001-12-10 三菱化学株式会社 ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU667533B2 (en) 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
CA2218601A1 (en) 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
CA2163716C (en) 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
DE19641466A1 (de) 1996-10-09 1998-04-16 Biotest Pharma Gmbh Orale Anwendung eines Immunglobulinpräparates zur Prävention des Hämolytischen Urämischen Syndroms sowie Präparat hierfür
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease

Also Published As

Publication number Publication date
NZ508119A (en) 2003-06-30
AU4090499A (en) 1999-12-06
EP1079856A4 (de) 2002-03-13
PT1079856E (pt) 2006-12-29
AU748852B2 (en) 2002-06-13
BR9910589A (pt) 2001-01-16
ZA200006370B (en) 2001-08-22
CA2328485A1 (en) 1999-11-25
KR20010052367A (ko) 2001-06-25
EP1079856B1 (de) 2006-08-09
IL139571A (en) 2009-09-22
NO20005833L (no) 2001-01-15
ES2270598T3 (es) 2007-04-01
US7846435B1 (en) 2010-12-07
DE69932719T2 (de) 2007-09-13
RU2217166C2 (ru) 2003-11-27
CN1301175A (zh) 2001-06-27
JP2002515230A (ja) 2002-05-28
NO20005833D0 (no) 2000-11-17
CN1330375C (zh) 2007-08-08
KR100548167B1 (ko) 2006-01-31
JP4044733B2 (ja) 2008-02-06
DE69932719D1 (de) 2006-09-21
NO326197B1 (no) 2008-10-13
IL139571A0 (en) 2002-02-10
WO1999059629A1 (en) 1999-11-25
CA2328485C (en) 2011-05-03
DK1079856T3 (da) 2006-12-04
HK1036215A1 (en) 2001-12-28
EP1079856A1 (de) 2001-03-07

Similar Documents

Publication Publication Date Title
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ATE322288T1 (de) Zusammensetzungen zur immunisierung sowie deren verwendung
EP2363404A3 (de) PSMA Antikörper
IL189629A0 (en) Compositions containing human ctla-4 antibodies
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
ATE412432T1 (de) Internalisierende erbb2 antikörper
DE60223340D1 (de) Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
ATE180974T1 (de) Zusammensetzungen und methoden zur behandlung von kleinzell und nicht-kleinzell lungenkrebsen
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
DE69932719D1 (de) Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
EP1370697A4 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion und verfahren zu deren verwendung
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1079856

Country of ref document: EP